The U.S. Food and Drug Administration (FDA) has approved the biologic Ilumya (tildrakizumab-asmn) for adults with active psoriatic arthritis (PsA). This medication was already approved for adults with moderate to severe plaque psoriasis.
In two clinical trials, 35 percent to 41 percent of people receiving Ilumya had at least a 20 percent improvement in arthritis activity after 24 weeks. This outcome was compared with 23 percent to 25 percent of those receiving a placebo (inactive treatment).
The new approval gives people living with PsA another treatment option to discuss with their healthcare team.
Ilumya is a formulation of tildrakizumab-asmn, a biologic medication that targets interleukin-23 (IL-23). IL-23 is a protein involved in the body’s immune response and inflammation. Ilumya works by blocking IL-23, helping reduce inflammation.
Ilumya is given as a subcutaneous (under-the-skin) injection by a healthcare provider. The dosing schedule depends on whether a person also has moderate-to-severe plaque psoriasis.
The FDA approval was based on two separate phase 3 clinical trials, called PsA2 and PsA3, involving 806 adults with active PsA. Participants received tildrakizumab or a placebo for 24 weeks. Some continued taking other arthritis medications during the studies.
Researchers measured how many participants achieved an American College of Rheumatology 20 (ACR20) response. This means they showed at least a 20 percent improvement in measures of arthritis activity, including tender and swollen joints.
At week 24, researchers found:
The results suggest that Ilumya can help reduce arthritis activity for some adults. But not everyone responded to treatment, and the trials didn’t directly compare tildrakizumab with other biologics.
Like other medications that affect the immune system, Ilumya has potential risks.
In the PsA clinical trials, the most commonly reported adverse reactions occurring in at least 3 percent of people taking Ilumya and more often than with placebo were:
Ilumya may increase the risk of infections. Before starting treatment, your healthcare provider should check you for tuberculosis and discuss potential side effects with you.
Having another FDA-approved treatment option may be helpful for people whose PsA symptoms aren’t well controlled or who are exploring different approaches with their rheumatologist.
Ilumya’s dosing schedule may also be an important consideration. The medication is given by a healthcare provider rather than self-injected at home. Maintenance doses are typically scheduled every 12 weeks.
If you’re living with PsA and aren’t satisfied with your current treatment, you may want to explore other options. Talk with your rheumatologist about which treatments might best fit your symptoms, needs, and goals.
Get updates directly to your inbox.
Become a member to get even more
This is a member-feature!
Sign up for free to view article comments.
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.